Pier Giorgio Cojutti1,2, Anna Candoni3, Davide Lazzarotto3, Nicholas Rabassi3, Renato Fanin2,3, William Hope4, Federico Pea1,2. 1. Institute of Clinical Pharmacology, Santa Maria della Misericordia University Hospital, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy. 2. Department of Medicine, University of Udine, Udine, Italy. 3. Division of Haematology, Santa Maria della Misericordia University Hospital, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy. 4. Antimicrobial Pharmacodynamics and Therapeutics, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
Abstract
AIMS: The aim of this study was to determine clinical variables associated with posaconazole exposure among adult patients with haematological malignancies who received posaconazole tablets for prophylaxis of invasive fungal infections (IFIs). METHODS: The study population included adult patients with haematological malignancies who received posaconazole delayed-release tablets for prophylaxis of IFIs after induction chemotherapy for acute leukaemia or graft-versus-host-disease (GVHD) complicating hematopoietic stem cell transplantation (HSCT) in the period January 2016-December 2017. RESULTS: Sixty-six consecutive patients with 176 posaconazole Cmin were included for evaluation in the study. Subtherapeutic posaconazole concentrations (< 0.7 mg l-1 ) were observed at least once in 33.3% of patients (22/66), and overall in 17.0% of therapeutic drug monitoring (TDM) episodes (30/176). At multilevel linear regression, use of PPIs (P = 0.008), use of intermediate or high dose steroids (>0.7 mg kg-1 daily) (P = 0.022) and male gender (P = 0.025) were significantly associated with decreased Cmin , whereas time from starting therapy (P = 0.032) was associated with increased Cmin in our patient population. CONCLUSION: Posaconazole exposure during treatment with delayed-released tablet formulation may be affected by the use of PPIs and/or of intermediate or high dose steroids.
AIMS: The aim of this study was to determine clinical variables associated with posaconazole exposure among adult patients with haematological malignancies who received posaconazole tablets for prophylaxis of invasive fungal infections (IFIs). METHODS: The study population included adult patients with haematological malignancies who received posaconazole delayed-release tablets for prophylaxis of IFIs after induction chemotherapy for acute leukaemia or graft-versus-host-disease (GVHD) complicating hematopoietic stem cell transplantation (HSCT) in the period January 2016-December 2017. RESULTS: Sixty-six consecutive patients with 176 posaconazole Cmin were included for evaluation in the study. Subtherapeutic posaconazole concentrations (< 0.7 mg l-1 ) were observed at least once in 33.3% of patients (22/66), and overall in 17.0% of therapeutic drug monitoring (TDM) episodes (30/176). At multilevel linear regression, use of PPIs (P = 0.008), use of intermediate or high dose steroids (>0.7 mg kg-1 daily) (P = 0.022) and male gender (P = 0.025) were significantly associated with decreased Cmin , whereas time from starting therapy (P = 0.032) was associated with increased Cmin in our patient population. CONCLUSION:Posaconazole exposure during treatment with delayed-released tablet formulation may be affected by the use of PPIs and/or of intermediate or high dose steroids.
Authors: Wendy M Kersemaekers; Peter Dogterom; Jialin Xu; Eugene E Marcantonio; Rik de Greef; Hetty Waskin; Marlou L P S van Iersel Journal: Antimicrob Agents Chemother Date: 2015-03-30 Impact factor: 5.191
Authors: Stephen Ph Alexander; Doriano Fabbro; Eamonn Kelly; Neil V Marrion; John A Peters; Elena Faccenda; Simon D Harding; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies Journal: Br J Pharmacol Date: 2017-12 Impact factor: 8.739
Authors: C Boglione-Kerrien; S Picard; C Tron; S Nimubona; J-P Gangneux; S Lalanne; F Lemaitre; E Bellissant; M-C Verdier; A Petitcollin Journal: J Cancer Res Clin Oncol Date: 2017-09-20 Impact factor: 4.553
Authors: D Andes; K Marchillo; R Conklin; Gopal Krishna; Farkad Ezzet; Anthony Cacciapuoti; David Loebenberg Journal: Antimicrob Agents Chemother Date: 2004-01 Impact factor: 5.191
Authors: Oliver A Cornely; Rafael F Duarte; Shariq Haider; Pranatharthi Chandrasekar; David Helfgott; Javier López Jiménez; Anna Candoni; Issam Raad; Michel Laverdiere; Amelia Langston; Nicholas Kartsonis; Marlou Van Iersel; Nancy Connelly; Hetty Waskin Journal: J Antimicrob Chemother Date: 2016-03-08 Impact factor: 5.790
Authors: Anne-Grete Märtson; Anette Veringa; Edwin R van den Heuvel; Martijn Bakker; Daan J Touw; Tjip S van der Werf; Lambert F R Span; Jan-Willem C Alffenaar Journal: Mycoses Date: 2019-06-18 Impact factor: 4.377